• Galectin Therapeutics posted a net loss of USD 5.05 million, or USD 0.08 per share, for quarter ended March 31, 2026, narrowing from a net loss of USD 9.63 million, or USD 0.15 per share, a year earlier.
• Operating loss narrowed to USD 4.08 million as research and development expense dropped 65.6% to USD 2.23 million.
• General and administrative expense rose 30.7% to USD 1.85 million, driven by higher non-cash stock-based compensation expense of about USD 302,000.
• Cash and cash equivalents fell to USD 14.11 million at March 31, 2026 from USD 17.72 million at Dec. 31, 2025, while net cash used in operating activities improved to USD 3.87 million from USD 7.69 million.
• Management said it had USD 10 million of available borrowings under a related-party line of credit and expects cash, including that facility, to fund currently planned operations through May 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galectin Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-021495), on May 15, 2026, and is solely responsible for the information contained therein.